Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer
Abstract Ubamatamab, a Mucin 16 (MUC16) × cluster of differentiation 3 (CD3) bispecific antibody that promotes T‐cell‐mediated cytotoxicity of MUC16‐expressing cells, is being investigated for the treatment of ovarian cancer. Intravenous administration of ubamatamab, with or without the anti‐program...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.70082 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846110154213294080 |
|---|---|
| author | Min Zhu Priyanka Madia Alison Crawford Jurriaan Brouwer‐Visser Pamela Krueger Lauric Haber Mary Peterman Thomas S. Uldrick Elizabeth Miller John D. Davis Marc W. Retter |
| author_facet | Min Zhu Priyanka Madia Alison Crawford Jurriaan Brouwer‐Visser Pamela Krueger Lauric Haber Mary Peterman Thomas S. Uldrick Elizabeth Miller John D. Davis Marc W. Retter |
| author_sort | Min Zhu |
| collection | DOAJ |
| description | Abstract Ubamatamab, a Mucin 16 (MUC16) × cluster of differentiation 3 (CD3) bispecific antibody that promotes T‐cell‐mediated cytotoxicity of MUC16‐expressing cells, is being investigated for the treatment of ovarian cancer. Intravenous administration of ubamatamab, with or without the anti‐programmed cell death‐1 inhibitor cemiplimab, is being evaluated in a first‐in‐human study in patients with recurrent ovarian cancer. In vitro cytotoxicity and cytokine data and projected ubamatamab human pharmacokinetic (PK) profiles scaled with monkey PK parameters enabled starting‐dose selection in humans. Mouse tumor regression studies identified ubamatamab effective concentrations. Preclinical and clinical PK, cytokine, safety, and efficacy data from dose escalation were integrated to determine expansion regimens. A starting dose of 0.1 mg was selected, which showed acceptable safety in patients. A step‐up dosing approach was used to effectively manage cytokine release syndrome. Mouse tumor regression models suggested an ubamatamab efficacious concentration range of 0.4–50 mg/L, consistent with clinical activity observed at ubamatamab trough concentrations ≥5 mg/L. Integrating preclinical and clinical data determined a target trough concentration range of 5–30 mg/L, which supports evaluation of ubamatamab 250 mg with or without cemiplimab and 800 mg monotherapy once every 3 weeks in expansion cohorts. Preclinical data (cytokine release, tumor regression, monkey PK) had translational value in supporting regimen selection in dose escalation and subsequently in dose expansion after integration with patient data from dose escalation. |
| format | Article |
| id | doaj-art-0c56df2454184f7aa3b59b0a9bdc2a8a |
| institution | Kabale University |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-0c56df2454184f7aa3b59b0a9bdc2a8a2024-12-24T15:26:30ZengWileyClinical and Translational Science1752-80541752-80622024-12-011712n/an/a10.1111/cts.70082Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancerMin Zhu0Priyanka Madia1Alison Crawford2Jurriaan Brouwer‐Visser3Pamela Krueger4Lauric Haber5Mary Peterman6Thomas S. Uldrick7Elizabeth Miller8John D. Davis9Marc W. Retter10Regeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USARegeneron Pharmaceuticals, Inc. Tarrytown New York USAAbstract Ubamatamab, a Mucin 16 (MUC16) × cluster of differentiation 3 (CD3) bispecific antibody that promotes T‐cell‐mediated cytotoxicity of MUC16‐expressing cells, is being investigated for the treatment of ovarian cancer. Intravenous administration of ubamatamab, with or without the anti‐programmed cell death‐1 inhibitor cemiplimab, is being evaluated in a first‐in‐human study in patients with recurrent ovarian cancer. In vitro cytotoxicity and cytokine data and projected ubamatamab human pharmacokinetic (PK) profiles scaled with monkey PK parameters enabled starting‐dose selection in humans. Mouse tumor regression studies identified ubamatamab effective concentrations. Preclinical and clinical PK, cytokine, safety, and efficacy data from dose escalation were integrated to determine expansion regimens. A starting dose of 0.1 mg was selected, which showed acceptable safety in patients. A step‐up dosing approach was used to effectively manage cytokine release syndrome. Mouse tumor regression models suggested an ubamatamab efficacious concentration range of 0.4–50 mg/L, consistent with clinical activity observed at ubamatamab trough concentrations ≥5 mg/L. Integrating preclinical and clinical data determined a target trough concentration range of 5–30 mg/L, which supports evaluation of ubamatamab 250 mg with or without cemiplimab and 800 mg monotherapy once every 3 weeks in expansion cohorts. Preclinical data (cytokine release, tumor regression, monkey PK) had translational value in supporting regimen selection in dose escalation and subsequently in dose expansion after integration with patient data from dose escalation.https://doi.org/10.1111/cts.70082 |
| spellingShingle | Min Zhu Priyanka Madia Alison Crawford Jurriaan Brouwer‐Visser Pamela Krueger Lauric Haber Mary Peterman Thomas S. Uldrick Elizabeth Miller John D. Davis Marc W. Retter Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer Clinical and Translational Science |
| title | Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer |
| title_full | Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer |
| title_fullStr | Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer |
| title_full_unstemmed | Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer |
| title_short | Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer |
| title_sort | translational findings support regimen selection for first in human study of ubamatamab muc16 cd3 bispecific antibody in patients with recurrent ovarian cancer |
| url | https://doi.org/10.1111/cts.70082 |
| work_keys_str_mv | AT minzhu translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT priyankamadia translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT alisoncrawford translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT jurriaanbrouwervisser translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT pamelakrueger translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT laurichaber translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT marypeterman translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT thomassuldrick translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT elizabethmiller translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT johnddavis translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer AT marcwretter translationalfindingssupportregimenselectionforfirstinhumanstudyofubamatamabmuc16cd3bispecificantibodyinpatientswithrecurrentovariancancer |